Inactivation of HNSCC cells by 90Y-labeled cetuximab strictly depends on the number of induced DNA double-strand breaks

Journal of Nuclear Medicine

Volumn 54, Issue 3, 2013, Pages 416-423

  Saker, Jarob ^a   Kriegs, Malte ^a   Zenker, Martin ^b   Heldt, Jan Martin ^b   Eke, Iris ^c   Pietzsch, Hans Jürgen ^b   Grénman, Reidar ^d   Cordes, Nils ^c,e   Petersen, Cordula ^a   Baumann, Michael ^c,e   Steinbach, Jörg ^b   Dikomey, Ekkehard ^a   Kasten Pisula, Ulla ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

^e UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

90Y Y CHXA DTPA cetuximab; Cell inactivation; Double strand breaks; EGFR; Targeted radioimmunotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; BINDING PROTEIN; CETUXIMAB Y 90; DOUBLE STRANDED DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA HISTONE H2AX; HISTONE H2AX; PENTETIC ACID; PROTEIN P53 BINDING PROTEIN 1; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL KILLING; CELL MEMBRANE; CELL SURVIVAL; COLONY FORMATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA REPAIR; DNA STRAND BREAKAGE; FLUORESCENCE ACTIVATED CELL SORTING; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; INCUBATION TEMPERATURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOIMMUNOTHERAPY; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; CARCINOMA, SQUAMOUS CELL; CELL DEATH; CELL LINE, TUMOR; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOCONJUGATES; RADIATION TOLERANCE; RADIOIMMUNOTHERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, SMALL INTERFERING; YTTRIUM RADIOISOTOPES;

EID: 84874904788     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.101857     Document Type: Article

References (24)

1. Bucci B, D'Agnano I, Botti C, et al. EGF-R expression in ductal breast cancer: proliferation and prognostic implications. Anticancer Res. 1997;17:769-774. (Pubitemid 27105566)
2. Kasten-Pisula U, Saker J, Eicheler W, et al. Cellular and tumor radiosensitivity is correlated to epidermal growth factor receptor protein expression level in tumors without egfr amplification. Int J Radiat Oncol Biol Phys. 2011;80: 1181-1188.
3. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002;62:7350-7356. (Pubitemid 36025259)
4. Baumann M, Krause M. Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. Radiother Oncol. 2004;72:257-266. (Pubitemid 39265378)
5. Eke I, Cordes N. Dual targeting of EGFR and focal adhesion kinase in 3D grown HNSCC cell cultures. Radiother Oncol. 2011;99:279-286.
6. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11:21-28.
7. Gurtner K, Deuse Y, Butof R, et al. Diverse effects of combined radiotherapy and EGFR inhibition with antibodies or TK inhibitors on local tumour control and correlation with EGFR gene expression. Radiother Oncol. 2011;99:323-330.
8. 90Y-labeled fully human antibody panitumumab. Mol Cancer Ther. 2010;9:2297-2308.
9. Niu G, Li Z, Xie J, Le QT, Chen X. PET of EGFR antibody distribution in head and neck squamous cell carcinoma models. J Nucl Med. 2009;50:1116-1123.
10. 90Yand 177Lu in tumorbearing nude mice after coupling to the internalizing antibody cetuximab. J Nucl Med. 2005;46:1898-1906. (Pubitemid 46196653)
11. Pfost B, Seidl C, Autenrieth M, et al. Intravesical alpha- radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice. J Nucl Med. 2009;50:1700-1708.
12. Ping Li W, Meyer LA, Capretto DA, Sherman CD, Anderson CJ. Receptorbinding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors. Cancer Biother Radiopharm. 2008;23:158-171. (Pubitemid 351630188)
13. Wen X, Wu QP, Ke S, et al. Conjugation with 111In-DTPA-poly(ethylene glycol) improves imaging of anti-EGF receptor antibody C225. J Nucl Med. 2001;42:1530- 1537. (Pubitemid 32953134)
14. Aerts HJ, Dubois L, Perk L, et al. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med. 2009;50: 123-131.
15. Dikomey E, Brammer I. Relationship between cellular radiosensitivity and non-repaired double-strand breaks studied for different growth states, dose rates and plating conditions in a normal human fibroblast line. Int J Radiat Biol. 2000;76:773-781. (Pubitemid 30352760)
16. Kasten-Pisula U, Tastan H, Dikomey E. Huge differences in cellular radiosensitivity due to only very small variations in double-strand break repair capacity. Int J Radiat Biol. 2005;81:409-419. (Pubitemid 41657557)
17. Diaz A, Suarez E, Blanco R, et al. Functional expression of human-epidermal-growthfactor receptor in a melanoma cell line. Biotechnol Appl Biochem. 2007;48:21-27. (Pubitemid 47425171)
18. Kriegs M, Kasten-Pisula U, Rieckmann T, Holst K, Dahm-Daphi J, Dikomey E. The epidermal growth factor receptor modulates DNA double strand break repair by regulating non-homologous end joining. DNA Repair (Amst). 2010;9:889-897.
19. Kawamoto T, Sato JD, Le A, Polikoff J, Sato GH, Mendelsohn J. Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci U S A. 1983;80:1337-1341. (Pubitemid 13082800)
20. Milenic DE, Brady ED, Brechbiel MW. Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov. 2004;3:488-499.
21. Dittmann K, Mayer C, Rodemann HP. Inhibition of radiation-induced EGFR nuclear import by C225 (cetuximab) suppresses DNA-PK activity. Radiother Oncol. 2005;76:157-161. (Pubitemid 41725442)
22. Cai Z, Chen Z, Bailey KE, Scollard DA, Reilly RM, Vallis KA. Relationship between induction of phosphorylated H2AX and survival in breast cancer cells exposed to 111In-DTPA-hEGF. J Nucl Med. 2008;49:1353-1361.
23. Lu C, Zhu F, Cho YY, et al. Cell apoptosis: requirement of H2AX in DNA ladder formation, but not for the activation of caspase-3. Mol Cell. 2006;23:121-132. (Pubitemid 43963445)
24. Torres LA, Perera A, Batista JF, et al. Phase I/II clinical trial of the humanized anti-EGF-r monoclonal antibody h-R3 labelled with 99mTc in patients with tumour of epithelial origin. Nucl Med Commun. 2005;26:1049-1057. (Pubitemid 41677593)